Allan Rubenstein Net Worth

The estimated Net Worth of Allan E Rubenstein is at least $6.14 million dollars as of 1 April 2020. Allan Rubenstein owns over 958 units of Cooper Companies stock worth over $439,357 and over the last 21 years he sold COO stock worth over $5,223,933. In addition, he makes $472,284 as Independent Vice Chairman of the Board et Lead Director at Cooper Companies.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Allan Rubenstein COO stock SEC Form 4 insiders trading

Allan has made over 35 trades of the Cooper Companies stock since 2003, according to the Form 4 filled with the SEC. Most recently he exercised 958 units of COO stock worth $103,953 on 1 April 2020.

The largest trade he's ever made was exercising 30,300 units of Cooper Companies stock on 7 March 2011 worth over $1,315,626. On average, Allan trades about 1,512 units every 59 days since 2003. As of 1 April 2020 he still owns at least 4,049 units of Cooper Companies stock.

You can see the complete history of Allan Rubenstein stock trades at the bottom of the page.

Allan Rubenstein biography

Dr. Allan E. Rubenstein M.D. is no longer serves as Independent Vice Chairman of the Board, Lead Director of the Company effective 03/2021. Dr. Rubenstein has served as our Vice Chairman and Lead Director since July 2002, and previously served as Chairman of the Board from July 1994 through July 2002. He served as Acting Chairman of the Board from April 1993 through June 1994. He is a Clinical Professor of Neurology and Pediatrics at New York University Langone Medical Center. Formerly, he was Chief Executive Officer of NexGenix Pharmaceuticals in NYC from 2003 to 2011. He currently serves as Chairman of the Scientific Advisory Boards of Plex Pharmaceuticals in San Diego and Coloursmith in Halifax, Nova Scotia, both privately-held technology companies. He is a member of the Board of Advisors of the Sackler School Graduate Program in Biomedical Sciences at Tufts University. He is also the Founder and Medical Director Emeritus of the Children’s Tumor Foundation and a consultant to the National Institutes of Health, the U.S. Food and Drug Administration and the U.S. Department of Defense, where he served as Chair of the US Army Neurofibromatosis Research Program Integration Panel in 2001. Dr. Rubenstein was a Trustee of the Connecticut River Museum in Essex, CT from 2014-2019 and presently is a Director of the Lunenburg, Nova Scotia DocFest Film Festival.

What is the salary of Allan Rubenstein?

As the Independent Vice Chairman of the Board et Lead Director of Cooper Companies, the total compensation of Allan Rubenstein at Cooper Companies is $472,284. There are 10 executives at Cooper Companies getting paid more, with Albert White having the highest compensation of $7,724,740.

How old is Allan Rubenstein?

Allan Rubenstein is 75, he's been the Independent Vice Chairman of the Board et Lead Director of Cooper Companies since 2002. There are 1 older and 18 younger executives at Cooper Companies. The oldest executive at Cooper Companies, Inc. is A. Thomas Bender, 80, who is the Independent Chairman of the Board.

What's Allan Rubenstein's mailing address?

Allan's mailing address filed with the SEC is C/O THE COOPER COMPANIES, INC., 6101 BOLLINGER CANYON ROAD, SUITE 500, SAN RAMON, CA, 94583.

Insiders trading at Cooper Companies

Over the last 21 years, insiders at Cooper Companies have traded over $45,273,696 worth of Cooper Companies stock and bought 5,157 units worth $1,262,486 . The most active insiders traders include Robert S Weiss, William A Kozy et Lawrence Erik Kurzius. On average, Cooper Companies executives and independent directors trade stock every 18 days with the average trade being worth of $1,325,775. The most recent stock trade was executed by Brian G Andrews on 5 September 2024, trading 24,788 units of COO stock currently worth $939,713.

What does Cooper Companies do?

company overview the cooper companies, inc. ("cooper"​) is a global medical device company publicly traded on the nyse euronext (nyse:coo). cooper is dedicated to being a quality of life company™ with a focus on delivering shareholder value. cooper operates through two business units, coopervision and coopersurgical. coopervision brings a refreshing perspective on vision care with a commitment to crafting a wide range of high-quality products for contact lens wearers and providing focused practitioner support. coopersurgical focuses on supplying women's health clinicians with market leading products and treatment options to improve the delivery of healthcare to women. headquartered in pleasanton, ca, cooper has approximately 9,000 employees with products sold in over 100 countries. for more information, please visit www.coopercos.com.

Complete history of Allan Rubenstein stock trades at Cooper Companies

Cooper Companies executives and stock owners

Cooper Companies executives and other stock owners filed with the SEC include:

• Albert White,
  President, Chief Executive Officer, Director
• Daniel McBride,
  Chief Operating Officer, Executive Vice President, President of CooperVision, Inc.
• Holly Sheffield,
  President - CooperSurgical
• Brian Andrews,
  Chief Financial Officer, Senior Vice President, Treasurer
• Albert G. White III,
  Pres, CEO & Non-Independent Director
• Agostino Ricupati,
  Senior Vice President - Finance and Tax, Chief Accounting Officer
• Daniel G. McBride Esq.,
  Exec. VP & COO
• Holly R. Sheffield,
  Pres of CooperSurgical, Inc.
• Brian G. Andrews,
  Exec. VP, CFO & Treasurer
• A. Thomas Bender,
  Independent Chairman of the Board
• Allan Rubenstein,
  Independent Vice Chairman of the Board, Lead Director
• Jody Lindell,
  Independent Director
• Gary Petersmeyer,
  Independent Director
• Colleen Jay,
  Independent Director
• William Kozy,
  Independent Director
• Robert Weiss,
  Director
• Teresa Madden,
  Independent Director
• Kim Duncan,
  Vice President of Investor Relations and Administration
• Randal Golden,
  Vice President, General Counsel, Secretary
• Juan Carlos Aragón,
  Pres of CooperVision Specialty EyeCare Division
• Mark J. Drury,
  VP, Gen. Counsel & Corp. Sec.
• Agostino Ricupati,
  Sr. VP of Fin. & Tax and Chief Accounting Officer
• Carol R Kaufman,
  VP Legal Affairs, Sec. and CAO
• Paul L Remmell,
  COO, VP Finance-CSI
• Tina Maloney,
  Corporate Controller
• Gregory W Matz,
  VP & CFO
• Stanley Md Zinberg,
  Director
• Michael Kalkstein,
  
• Nicholas J Pichotta,
  
• Rodney Folden,
  Corporate Controller
• Donald Press,
  Director
• Steven Rosenberg,
  Director
• Jeffrey Alan Mc Lean,
  Pres - U.S. Ops - CVI
• Dennis Murphy,
  President Americas, CVI
• Moses Marx,
  Director
• Andrew Sedgwick,
  Managing Dir., Europe of CVI
• Eugene J Midlock,
  Vice President, Taxes
• John J Calcagno,
  CFO and VP Bus. Dev.
• John Arthur Weber,
  Vice Pres Worldwide Ops-CVI
• J Christopher Marmo,
  VP, R&D of CooperVision, Inc.
• John D Fruth,
  Director
• B Norris Battin,
  
• Edgar J Cummins,
  Director
• Steven M Neil,
  CFO
• David Acosta,
  Treasurer
• Companies Inc Cooper,
  Director
• Gregory A Fryling,
  COO - CVI
• James M Welch,
  Vice President Intl Ops - CVI
• Stephen Whiteford,
  VP, Corporate Controller
• Robert D Auerbach,
  Special Advisor to the CEO
• Mark J Drury,
  VP, General Counsel & Sec.
• Maria Rivas,
  
• Gerard H Iii Warner,
  President, CooperVision, Inc.
• Nicholas Khadder,
  VP, General Counsel & Corp Sec
• Lawrence Erik Kurzius,
  
• Cynthia L Lucchese,